Cytori Announces Exercise in Full of Overallotment Option and Closing of Public Offering of Common Stock; Raises $19.3 Million in Net Proceeds
Cytori anticipates using the net proceeds from the offering for general corporate purposes, including sales and marketing activities, clinical studies, research and development, capital expenditures, future acquisitions, working capital, and repayment of debt.
Jefferies & Company, Inc. acted as sole book-running manager for this offering. Registration statements relating to the securities described above have become effective by order or rule of the Securities and Exchange Commission ("SEC"). A final prospectus supplement relating to the offering has been filed with the SEC and is available on the SEC's website located at www.sec.gov. Copies of the final prospectus supplement relating to these securities may be obtained from Equity Syndicate Prospectus Department, Jefferies & Company, 520 Madison Avenue, 12th Floor, New York, NY, 10022, at 877-547-6340 and at Prospectus_Department@Jefferies.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About Cytori Therapeutics, Inc.
Cytori develops and commercializes medical technologies that enable the practice of regenerative medicine.